
    
      This is an open, one-arm, prospective clinical collaborative study to observe the combined
      treatment plan of Orelabrutinib combined with PD-1 and fotemustine in newly treated patients
      with primary central nervous system lymphoma (PCNSL) efficacy and safety.A total of 40
      patients plan to participate in the study. The primary endpoints were complete remission
      rate（CRR） , and secondary endpoints including objective response rate (ORR)、disease control
      rate(DCR) 、progression-free survival (PFS) 、overall survival (OS), and adverse events(ADR).
    
  